Ketamine is a powerful and rapid-acting antidepressant but has no regulatory authorization for any psychiatric illness. The S-enantiomer of ketamine, esketamine, was approved by the FDA in 2019 as adjunctive therapy for treatment-resistant depression. Substantial controversy exists as to whether there is a significant clinical difference between intravenous (IV) ketamine racemate and intranasal...
PURPOSE: Increased depression, anxiety and stress symptoms are associated with reduced mindfulness levels and coping skills. This study primarily aimed to investigate (1) the relationships between mindfulness, coping styles, depression, anxiety and stress and (2) mindfulness and coping styles as predictors of depression, anxiety and stress in adults who stutter. A secondary aim was to compare...
Online Mindfulness-Based Cognitive Therapy (MBCT) is a promising intervention for mental health, but its effectiveness in reducing depressive symptoms remains underexplored. While key mechanisms of change have been identified in traditional MBCT, their role in online delivery formats needs further investigation. This study aimed to evaluate the effectiveness of synchronous and asynchronous...
Electroconvulsive therapy (ECT) has long been considered the main method of treatment for patients with resistant major depressive disorder (MDD). Recent studies have shown that ketamine infusion can also effectively improve treatment-resistant MDD. Thus, we conducted this meta-analysis to compare the efficacy of ketamine with ECT for treating treatment-resistant depression. We systematically...
Major depressive disorder (MDD) is increasingly viewed as a disorder of impaired neural plasticity, yet the mechanisms underlying diverse antidepressant classes - glutamatergic (e.g., ketamine), monoaminergic (e.g., selective serotonin reuptake inhibitors (SSRIs)), and GABAergic (e.g., neurosteroids) - remain incompletely integrated. The objective of this study was to extend a...
To evaluate the efficacy of integrating Solution-Focused Brief Therapy (SFBT) and Mindfulness-Based Cognitive Therapy (MBCT) in alleviating psychological distress and improving functional outcomes in patients with post-stroke depression (PSD). A controlled study enrolled 60 PSD patients from a tertiary hospital in Jiangxi. Participants were allocated to a control group (n = 29) or an...
Psychological distress, including depression, anxiety, and stress, is highly prevalent among adults with cancer. Mindfulness-based interventions (MBIs), such as Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT), are increasingly used to address these symptoms. However, no prior review has comprehensively stratified MBI effects across intervention types,...
Disruptions in sleep, circadian rhythms, and neural plasticity are closely linked to the pathophysiology and treatment of depression. Acute sleep deprivation (SD) produces rapid but transient antidepressant effects, yet the underlying mechanisms remain poorly understood. Using a mouse model of stress-induced depression, we found altered sleep architecture, impaired sleep homeostasis, and...
BACKGROUND: Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid antidepressant effects and has shown promise in reducing alcohol use, and acceptance and commitment therapy (ACT) can be effective for both substance use and mood disorders. This study explores the...
Abstract: After an episode of painful ovarian torsion, I accepted a surgeon's counsel to undergo a hysterectomy/oophorectomy at the age of forty-six. The sudden menopause this surgery brought on intensified a chronic depression. Several decades later, after undergoing ketamine infusion treatments for my depression, I recognized that surgery as an experience of iatrogenic harm, part of the...